<DOC>
	<DOCNO>NCT01812759</DOCNO>
	<brief_summary>The goal clinical research study learn fentanyl nasal spray help decrease pain related cancer use drug pain . Researchers also want know drug help decrease length stay Emergency Department . In study , fentanyl nasal spray compare placebo nasal spray . A placebo drug . It look like study drug design treat disease illness . It design study compare study spray learn study spray real effect . You also give intravenous ( IV ) pain drug . You give drug even decide take part study .</brief_summary>
	<brief_title>Fentanyl Breakthrough Pain Emergency Department</brief_title>
	<detailed_description>Study Groups : If agree take part study , randomly assign ( flip coin ) receive either fentanyl nasal spray placebo nasal spray . You equal chance assign either group . Neither study staff know receive study spray placebo . However , need safety , study staff able find receiving . Study Visit Study Treatment : During stay Emergency Department today , follow test procedure perform : - Your vital sign ( blood pressure , heart rate , temperature , breathe rate ) record . - Information medical record age , sex , race , status disease , drug may take pain . - The study nurse also ask question pain . It take 5 minute answer question . You begin study treatment either fentanyl nasal spray placebo nasal spray . The study nurse help use nasal spray . You stay Emergency Department monitor 8 hour treatment administer . During time , ask pain side effect may . The study nurse also monitor IV pain drug level vital sign . Length Treatment : Your active participation study monitor 8 hour , time either discharge go home admit hospital base pain response health problem may find visit Emergency Department . Follow-Up Phone Call : About 24 hour participation , study nurse call phone ask experience side effect since finish study treatment . The phone call last 5 minute . If still inpatient hospital , study nurse may visit ask question person . This investigational study . Fentanyl nasal spray FDA approve commercially available treatment pain . It 's use help cancer pain Emergency Department investigational . Up 60 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Emergencies</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<mesh_term>Hydromorphone</mesh_term>
	<criteria>1 . Cancer patient present Emergency Department treatment acute breakthrough pain already receive tolerant opioid therapy underlie persistent cancer pain . ( Patients consider opioid tolerant take least : 60 mg oral morphine/day , 25 mcg transdermal fentanyl/hour , 30 mg oral oxycodone/day , 8 mg oral hydromorphone/day , 25 mg oral oxymorphone/day , equianalgesic dose another opioid week longer . ) 2 . Patients must severe pain 11point Numeric Rating Scale ( NRS 710 ) 3 . Breakthrough cancer pain must sufficient severity warrant use intravenous opioids judgment treat emergency physician 4 . Age 18 75 year 5 . Able understand description study give inform consent 6 . Patients must willing capable provide frequent pain assessment 8 hour 7 . Englishspeaking 1 . Patients approach acute distress exhibit symptom ( dyspnea , uncontrolled nausea/vomiting vertigo ) extent impairs ability understand evaluate inform consent 2 . Patients participate clinical trial pain 3 . Patients already tolerant opioids 4 . Patients , judgment treat clinician , suspected hepatic renal failure 5 . Patients pregnant lactate 6 . Patients know allergy significant reaction fentanyl , component IN formulation , hydromorphone , opioids 7 . Patients already high morphine equivalent daily dose ( MEDDs ) ( &gt; 500 mg/day ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pain</keyword>
	<keyword>Breakthrough cancer pain</keyword>
	<keyword>Emergency Department</keyword>
	<keyword>ED</keyword>
	<keyword>Fentanyl nasal spray</keyword>
	<keyword>Lazanda</keyword>
	<keyword>Placebo nasal spray</keyword>
	<keyword>Hydromorphone PCA</keyword>
	<keyword>Dilaudid</keyword>
</DOC>